{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T06:00:09Z","timestamp":1780898409595,"version":"3.54.1"},"reference-count":41,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J Artif Organs"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Hemorrhagic events are the most frequently reported complications during extracorporeal membrane oxygenation (ECMO). Anticoagulation, and in particular, unfractionated heparin (UFH), is commonly used and is often monitored by the activated partial thromboplastin time (aPTT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      A retrospective single-center analysis of adult patients undergoing venovenous (VV) ECMO between June 2018 and August 2021 was performed (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200943). The primary aim of this study was to compare aPTT values with major bleeding events or complications in patients receiving VV-ECMO.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Bleeding complications were observed in 16 (37%) of patients. The mean heparin dose was significantly higher in the bleeding group versus non- bleeding group for the aPTT target ranges of 40\u201360\u2009s (12.7\u2009\u00b1\u20098.07 vs 7.82\u2009\u00b1\u20092.65\u2009IU\/kg\/h,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.004) and 63\u201383\u2009s (12.6\u2009\u00b1\u20095.78 vs 9.06\u2009\u00b1\u20094.71\u2009IU\/kg\/h,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.0002). When comparing bleeding versus nonbleeding groups, there was no difference in the mean aPTT for all aPTT target ranges. In the aPTT 40\u201360\u2009s range group, the mean aPTT 24\u2009h prior to a bleeding event was 63.2\u2009\u00b1\u200918.6\u2009s, higher than the set target range.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In patients undergoing VV-ECMO, major bleeding events did not equate to higher aPTT levels. However, higher mean heparin doses were associated with higher hemorrhagic complications. Our findings suggest that lower aPTT levels may be reasonable to prevent bleeding events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03913988261445016","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T07:02:07Z","timestamp":1779519727000},"page":"391-401","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Activated partial thromboplastin time and hemorrhagic events in adults undergoing venovenous extracorporeal membrane oxygenation"],"prefix":"10.1177","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4960-7446","authenticated-orcid":false,"given":"Sean K","family":"O\u2019Brien","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA, USA"},{"name":"Martin Army Community Hospital, Fort Benning, GA, USAA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russel J","family":"Roberts","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel P","family":"Rosovsky","sequence":"additional","affiliation":[{"name":"Department of Medicine, Massachusetts General Hospital, Boston, MA, USA"},{"name":"Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6646-8680","authenticated-orcid":false,"given":"Natasha D","family":"Lopez","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-015-1678-7"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2013.09.008"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/MAT.0000000000001216"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.9302"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0240117"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1441-2772(23)01792-1"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00352"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201605-364SR"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/aor.12335"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-021-06593-x"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrtlng.2023.05.003"},{"key":"e_1_3_2_13_2","first-page":"5579936","article-title":"Monitoring unfractionated heparin in adult patients undergoing extracorporeal membrane oxygenation (ECMO): ACT, APTT, or ANTI-XA?","volume":"2021","author":"Nguyen TP","year":"2021","unstructured":"Nguyen TP, Phan XT, Huynh DQ, et al. Monitoring unfractionated heparin in adult patients undergoing extracorporeal membrane oxygenation (ECMO): ACT, APTT, or ANTI-XA?. Crit Care Res Pract 2021; 2021: 5579936.","journal-title":"Crit Care Res Pract"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/MAT.0000000000001652"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-2726-9"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1055\/a-1508-8230"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2859"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2857"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1616068"},{"issue":"2","key":"e_1_3_2_20_2","first-page":"170","article-title":"Hemostasis changes during veno-venous extracorporeal membrane oxygenation for respiratory support in adults","volume":"82","author":"Panigada M","year":"2016","unstructured":"Panigada M, Artoni A, Passamonti SM, et al. Hemostasis changes during veno-venous extracorporeal membrane oxygenation for respiratory support in adults. Minerva Anestesiol 2016; 82(2): 170\u2013179.","journal-title":"Minerva Anestesiol"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-016-0196-7"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/MAT.0000000000001004"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-87026-z"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227793"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/aor.12979"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11092314"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2019.09.013"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1636840"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202305-0896OC"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-017-0275-4"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/aor.14267"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1177\/0885066618776937"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15703"},{"issue":"11","key":"e_1_3_2_34_2","article-title":"Anti-factor-Xa and activated partial thromboplastin time concordance and outcomes in adults undergoing extracorporeal membrane oxygenation: a secondary analysis of the pilot low-dose heparin in critically ill patients undergoing extracorporeal membrane oxygenation randomized trial","volume":"5","author":"Aubron C","year":"2023","unstructured":"Aubron C, Chapalain X, Bailey M, et al. Anti-factor-Xa and activated partial thromboplastin time concordance and outcomes in adults undergoing extracorporeal membrane oxygenation: a secondary analysis of the pilot low-dose heparin in critically ill patients undergoing extracorporeal membrane oxygenation randomized trial. Crit Care Explor 2023; 5(11): e0999.","journal-title":"Crit Care Explor"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2024.06.008"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/MAT.0000000000002100"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-021-03554-0"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1697950"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2013-0572-OA"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2015.07.046"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2017.11.05"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/clc.24273"}],"container-title":["The International Journal of Artificial Organs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03913988261445016","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03913988261445016","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03913988261445016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T05:39:27Z","timestamp":1780897167000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03913988261445016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1177\/03913988261445016"],"URL":"https:\/\/doi.org\/10.1177\/03913988261445016","relation":{},"ISSN":["0391-3988","1724-6040"],"issn-type":[{"value":"0391-3988","type":"print"},{"value":"1724-6040","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]}}}